Ofatumumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Sclerosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Multiple Sclerosis
NCT04926818 · Novartis Pharmaceuticals
2021-10-05 – 2031-02-28 · Multiple Sclerosis (MS)
What this study did
NCT06869785 · Novartis Pharmaceuticals
2025-03-13 – 2030-03-23 · Relapsing Multiple Sclerosis (RMS)
What this study did
NCT03650114 · Novartis Pharmaceuticals
2018-12-28 – 2028-09-30 · Relapsing Multiple Sclerosis
What this study did
NCT04788615 · Novartis Pharmaceuticals
2021-07-23 – 2025-11-04 · Multiple Sclerosis
What this study did
NCT04353492 · Novartis Pharmaceuticals
2020-07-14 – 2025-03-11 · Relapsing Multiple Sclerosis
What this study did
NCT04510220 · Brigham and Women's Hospital
2020-09-21 – 2022-12-28 · Relapsing Multiple Sclerosis
What this study did
Other / comorbidity
NCT01077518 · Novartis Pharmaceuticals
2010-08-26 – 2018-12-26 · Lymphoma, Follicular
What this study did
NCT01039376 · Novartis Pharmaceuticals
2010-05-06 – 2018-06-26 · Leukaemia, Lymphocytic, Chronic
What this study did
NCT00748189 · Novartis Pharmaceuticals
2008-12-22 – 2018-05-17 · Leukaemia, Lymphocytic, Chronic
What this study did
NCT01920477 · Novartis Pharmaceuticals
2013-08-13 – 2018-01-11 · Pemphigus Vulgaris
What this study did
NCT01678430 · University of Liverpool
2011-12 – 2017-12 · Chronic Lymphocytic Leukaemia
What this study did
NCT00824265 · Novartis Pharmaceuticals
2009-03-12 – 2017-10-25 · Leukaemia, Lymphocytic, Chronic
What this study did
NCT01313689 · Novartis Pharmaceuticals
2011-04-14 – 2017-04-24 · Leukaemia
What this study did
NCT01200589 · Novartis Pharmaceuticals
2010-10-11 – 2016-12-19 · Non-Hodgkin's Lymphoma
What this study did
NCT02613910 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2015-12-23 – 2016-03-23 · Pemphigus
What this study did
NCT01014208 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2010-03 – 2014-11 · Lymphoma, Large-Cell, Diffuse
What this study did
NCT00611455 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2008-01-01 – 2013-07-15 · Arthritis, Rheumatoid
What this study did
NCT00603525 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2008-01 – 2013-07 · Arthritis, Rheumatoid
What this study did
Phase 2 (76)
Multiple Sclerosis
NCT03249714 · Novartis Pharmaceuticals
2018-03-15 – 2020-07-29 · Relapsing Multiple Sclerosis
What this study did
Other / comorbidity
NCT01361711 · Northwestern University
2011-06 – 2027-05 · Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
What this study did
NCT01286272 · National Cancer Institute (NCI)
2011-04-28 – 2025-09-02 · Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
What this study did
NCT01258933 · M.D. Anderson Cancer Center
2011-07-06 – 2024-10-18 · Leukemia, Lymphoma
What this study did
NCT01496976 · H. Lee Moffitt Cancer Center and Research Institute
2012-03-30 – 2024-09-11 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02388048 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2015-10 – 2024-04-03 · Leukemia, Lymphoblastic, Chronic
What this study did
NCT01527149 · Roswell Park Cancer Institute
2011-12-06 – 2024-01-11 · Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
What this study did
NCT01145209 · National Heart, Lung, and Blood Institute (NHLBI)
2010-07-01 – 2023-09-15 · Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
What this study did
NCT01437709 · Memorial Sloan Kettering Cancer Center
2011-09 – 2023-09-12 · Mantle Cell Lymphoma
What this study did
NCT01243190 · M.D. Anderson Cancer Center
2011-03 – 2023-03-28 · Chronic Lymphocytic Leukemia
What this study did
NCT02199184 · M.D. Anderson Cancer Center
2015-01-14 – 2023-02-17 · AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
What this study did
NCT03280160 · PETHEMA Foundation
2017-09-07 – 2022-09 · Chronic Lymphocytic Leukemia
What this study did
NCT02710643 · Fondazione Italiana Linfomi - ETS
2014-10 – 2022-04-07 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade 3A
What this study did
NCT01555541 · C. Babis Andreadis
2012-05-25 – 2021-07-01 · Diffuse Large Cell Lymphoma Relapsed/Refractory
What this study did
NCT01190449 · Alliance for Clinical Trials in Oncology
2011-08 – 2020-10-15 · Lymphoma
What this study did
NCT02135133 · Dana-Farber Cancer Institute
2014-06 – 2020-10-06 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01716208 · Joseph Tuscano
2013-01-14 – 2020-10-01 · Chronic Lymphocytic Leukemia
What this study did
NCT01444716 · M.D. Anderson Cancer Center
2011-12-15 – 2020-06-11 · Chronic Lymphocytic Leukemia
What this study did
NCT01613300 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
2012-04-04 – 2020-06 · B-Cell Lymphomas
What this study did
NCT01363128 · M.D. Anderson Cancer Center
2011-07-12 – 2020-04-08 · Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma, CD20 Positive, Childhood Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma
What this study did
NCT03488225 · M.D. Anderson Cancer Center
2018-03-28 – 2020-04-02 · Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
What this study did
NCT01497496 · H. Lee Moffitt Cancer Center and Research Institute
2012-01-26 – 2020-03-20 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02689141 · German CLL Study Group
2016-02-04 – 2020-02-06 · Chronic Lymphocytic Leukemia
What this study did
NCT01329900 · M.D. Anderson Cancer Center
2011-08-22 – 2019-07-21 · Lymphoma
What this study did
NCT02394106 · Istituto Giannina Gaslini
2015-07 – 2019-06 · Nephrotic Syndrome
What this study did
NCT02394119 · Istituto Giannina Gaslini
2015-06 – 2019-05 · Nephrotic Syndrome
What this study did
NCT01481272 · Polish Lymphoma Research Group
2011-11 – 2018-12 · Diffuse Large B Cell Lymphoma
What this study did
NCT01762202 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2013-11-05 – 2018-10 · B-cell Lymphoid Leukemia, Young Patients
What this study did
NCT01612988 · French Innovative Leukemia Organisation
2012-07 – 2018-04 · B-cell Chronic Lymphocytic Leukemia (B-CLL)
What this study did
NCT01002755 · M.D. Anderson Cancer Center
2010-01-19 – 2018-01-31 · Chronic Lymphocytic Leukemia, Fatigue, Fever, Hypogammaglobulinemia, Lymphadenopathy, Lymphocytosis, Night Sweats, Paraproteinemia, Small Lymphocytic Lymphoma, Thrombocytopenia
What this study did
NCT01263418 · UNC Lineberger Comprehensive Cancer Center
2011-06 – 2018-01 · Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Low-Grade, Lymphoma, Intermediate-Grade
What this study did
NCT01455051 · Grupo Espanol de trasplantes hematopoyeticos y terapia celular
2011-10 – 2017-10 · Chronic Lymphocytic Leukemia
What this study did
NCT01024010 · Mayo Clinic
2010-03 – 2017-09-28 · Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
What this study did
NCT01532700 · University Health Network, Toronto
2012-02 – 2017-06-30 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT02419469 · M.D. Anderson Cancer Center
2015-11-13 – 2017-06-22 · Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
What this study did
NCT01626352 · SCRI Development Innovations, LLC
2012-10 – 2017-04 · Diffuse Large B-Cell Lymphoma
What this study did
NCT01848145 · SCRI Development Innovations, LLC
2013-07 – 2017-03 · Chronic Lymphocytic Leukemia
What this study did
NCT01465334 · Dana-Farber Cancer Institute
2011-12 – 2017-01 · CLL, SLL
What this study did
NCT01294579 · Novartis Pharmaceuticals
2011-05-17 – 2016-12-20 · Lymphoma, Non-Hodgkin
What this study did
NCT01681563 · Niguarda Hospital
2011-09 – 2016-12 · Chronic Lymphocytic Leukemia
What this study did
NCT01113632 · SCRI Development Innovations, LLC
2010-07 – 2016-08 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01171378 · University of Oxford
2011-04 – 2016-04-19 · Richter's Syndrome
What this study did
NCT02412267 · National Cancer Centre, Singapore
2011-04 – 2016-03 · Diffuse Large B-cell Lymphoma
What this study did
NCT01520922 · Novartis Pharmaceuticals
2012-03 – 2015-11 · Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
What this study did
NCT01187303 · University of Cologne
2011-05 – 2015-09 · Relapsed NLPHL
What this study did
NCT01119794 · Brown University
2010-07 – 2015-07 · Lymphoma, Non-Hodgkins
What this study did
NCT01376713 · Medical University of Vienna
2011-06 – 2015-05 · Stage III Melanoma, Stage IV Melanoma
What this study did
Phase 1/2 (10)
Other / comorbidity
NCT07871006 · Xijing Hospital
2025-10-01 – 2027-12-31 · Narcolepsy Type 1 (NT1)
What this study did
NCT05504694 · Tang-Du Hospital
2022-06-28 – 2026-07-31 · Neuromyelitis Optica Spectrum Disorder
What this study did
NCT01680965 · H. Lee Moffitt Cancer Center and Research Institute
2012-11-14 – 2020-08-30 · Chronic Graft Versus Host Disease
What this study did
NCT01458366 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2011-11-09 – 2020-07-23 · Non-Hodgkin's Lymphoma
What this study did
NCT01060384 · University of Nebraska
2010-03-29 – 2018-01-01 · Non-Hodgkin's Lymphoma
What this study did
NCT01515176 · National Cancer Institute (NCI)
2012-01 – 2016-07-19 · Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
What this study did
NCT01217749 · Pharmacyclics LLC.
2010-12 – 2014-05 · B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
What this study did
NCT01221103 · Southern Europe New Drug Organization
2010-04 – 2012-06 · Lymphoma, Mantle-Cell
What this study did
NCT00093314 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2004-10 – 2007-01 · Chronic Lymphocytic Leukemia
What this study did
NCT00092274 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2004-09 – 2005-01 · Lymphoma, Follicular
What this study did
Phase 1 (9)
Multiple Sclerosis
NCT07546110 · The Affiliated Hospital of Xuzhou Medical University
2026-05 – 2028-12-30 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT02614508 · Emory University
2016-01 – 2019-08 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT01352312 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2011-05-25 – 2018-05-10 · Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma
What this study did
NCT01768338 · Michael John Robertson
2013-02 – 2017-08-03 · Non-Hodgkin's Lymphoma
What this study did
NCT01691807 · Novartis Pharmaceuticals
2013-01 – 2015-12 · Cancer
What this study did
NCT01110031 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2010-05-13 – 2012-06-26 · Leukaemia, Lymphocytic, Chronic
What this study did
NCT00686868 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2008-06-13 – 2011-05-02 · Arthritis, Rheumatoid
What this study did
NCT00742144 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2008-09-19 – 2009-11-18 · Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
What this study did
Phase 4 (8)
Multiple Sclerosis
NCT05090371 · Novartis Pharmaceuticals
2022-03-02 – 2027-04-13 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT06444113 · Novartis Pharmaceuticals
2024-11-25 – 2026-10-29 · Multiple Sclerosis
What this study did
NCT05084638 · Novartis Pharmaceuticals
2022-01-25 – 2026-02-11 · Relapse Remitting Multiple Sclerosis
What this study did
NCT05199571 · Novartis Pharmaceuticals
2022-07-22 – 2025-02-13 · Relapsing Multiple Sclerosis
What this study did
NCT04667117 · Novartis Pharmaceuticals
2021-01-14 – 2023-07-06 · Relapsing Multiple Sclerosis
What this study did
NCT04869358 · Novartis Pharmaceuticals
2021-05-27 – 2023-06-13 · Relapsing Multiple Sclerosis
What this study did
NCT04878211 · Novartis Pharmaceuticals
2021-06-10 – 2023-04-14 · Relapsing Multiple Sclerosis (RMS)
What this study did
Other / comorbidity
NCT00802737 · GlaxoSmithKline
Run by former owner GlaxoSmithKline
2009-01 – 2013-05 · Leukaemia, Lymphocytic, Chronic
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Multiple Sclerosis
NCT07189325 · University Hospital, Montpellier
2026-06-15 – 2031-06 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
What this study did
Other / comorbidity
NCT06867991 · The First People's Hospital of Changzhou
2024-11-08 – 2027-11-08 · Anti-N-Methyl-D-Aspartate Receptor Encephalitis
What this study did
NCT02004522 · SecuraBio
2013-11 – 2021-06 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02049515 · SecuraBio
2013-12 – 2020-06-12 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01578707 · Pharmacyclics LLC.
2012-06 – 2018-10-25 · Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01580228 · Merck Sharp & Dohme LLC
2012-08 – 2014-12 · Chronic Lymphocytic Leukemia (CLL)
What this study did
Studied as part of a combination product (2)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 2 (2)
Other / comorbidity
NCT02877303 · M.D. Anderson Cancer Center
2016-11-01 – 2028-11-01 · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
What this study did
NCT03136146 · M.D. Anderson Cancer Center
2017-08-09 – 2027-08-01 · Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Other / comorbidity
NCT01659021 · Gilead Sciences
2012-12-04 – 2018-08-15 · Chronic Lymphocytic Leukemia
What this study did
Early phase / not applicable (1)
Multiple Sclerosis
NCT03500328 · Johns Hopkins University
2018-05-02 – 2026-08-31 · Multiple Sclerosis, Relapsing-Remitting
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Multiple Sclerosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ofatumumab: this drugApprovedMonoclonal antibodyCD20Reliable signal
NCT02792231: Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09)
NCT02792218: Annualized relapse rate (median 1.6-year follow-up): 0.11 ofatumumab vs 0.22 teriflunomide; difference -0.11 (95% CI -0.16 to -0.06).
AlemtuzumabApprovedMonoclonal antibodyCD52Partial signal
NCT00930553: Annualized Relapse Rate (ARR) (Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)): Alemtuzumab Treatment CAMMS323 Extension — Year 3: 0.19 relapses per participant per year; Year 4: 0.16 relapses per participant per year; Year 5: 0.15 relapses per participant per year; Year 6: 0.12 relapses per participant per year | Alemtuzumab Treatment CAMMS324 Extension — Year 3: 0.22 relapses per participant per year; Year 4: 0.24 relapses per participant per year; Year 5: 0.19 relapses per participant per year; Year 6: 0.16 relapses per participant per year
NCT00548405: Percentage of Participants With Sustained Accumulation of Disability (SAD) (Up to 2 years): Alemtuzumab 12 mg 12.71% (95% CI 9.89 to 16.27) vs Interferon Beta-1a 21.13% (95% CI 15.95 to 27.68)
BafiertamApprovedSmall moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
Cladribine (MAVENCLAD®)ApprovedSmall moleculeAdenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytesReliable signal
NCT00213135: Annualized Qualifying Relapse Rate (Week 96): Cladribine 5.25 mg/kg 0.15 relapses per year (95% CI 0.12 to 0.17) | Cladribine 3.5 mg/kg 0.14 relapses per year (95% CI 0.12 to 0.17) vs Placebo 0.33 relapses per year (95% CI 0.29 to 0.38)
CopaxoneApprovedPeptideMyelin basic protein-mimetic immunomodulationnot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Tecfidera)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Reliable signal
NCT00451451: Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo.
NCT00420212: Estimated proportion relapsed by 2 years: 27% with BG-12 240 mg twice daily and 26% with 240 mg three times daily vs 46% with placebo (P<0.001 for both comparisons) (DEFINE, N Engl J Med 2012).
Diroximel Fumarate (Vumerity)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Weak signal
NCT03093324: Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003.
Fampridine (Ampyra / Fampyra)ApprovedSmall moleculePotassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family)Partial signal
NCT00127530: Timed walk responders: fampridine 78/224 (35%) vs placebo 6/72 (8%), p<0.0001 (Goodman et al., Lancet 2009)
Fingolimod (Gilenya)ApprovedSmall moleculeSphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Reliable signal
NCT00289978: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47)
NCT00340834: Annualized relapse rate over 12 months: fingolimod 1.25 mg 0.20 (95% CI 0.16 to 0.26) and 0.5 mg 0.16 (95% CI 0.12 to 0.21) vs interferon beta-1a IM 0.33 (95% CI 0.26 to 0.42); p<0.001 for both comparisons. n=1,292 randomized (TRANSFORMS, Cohen 2010, NEJM).
Interferon Beta-1a (Avonex)ApprovedBiologic (subtype unspecified)Type I Interferon receptor (IFNAR)Weak signal
NCT00211887: ARR - PDEs (Baseline to Month 36): IFN + GA 0.12 relapses per year | IFB-1a 0.16 relapses per year vs Glatiramer 0.11 relapses per year
Interferon Beta-1bApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorPartial signal
NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS
NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinReliable signal
NCT00027300: Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001).
NCT03689972: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63)
Obinutuzumab
Approved(overall)
Monoclonal antibodyCD20
Partial signal(overall)
No reviewed efficacy summary in this indication
OcrelizumabApprovedMonoclonal antibodyCD20Partial signal
NCT05123703: Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk.
NCT01247324: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2)
Ocrevus ZunovoApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorPartial signal
NCT02047734: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose
NCT02294058: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period (12 months): Ozanimod 0.5 mg 0.241 relapses/year (95% CI 0.188 to 0.308) | Ozanimod 1 mg 0.181 relapses/year (95% CI 0.14 to 0.236) vs Interferon Beta-1a 0.35 relapses/year (95% CI 0.279 to 0.44)
Peginterferon Beta-1a (Plegridy)ApprovedBiologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)Reliable signal
NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481)
NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037).
PF-05280586
Approved(overall)
Biologic (subtype unspecified)CD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
PonesimodApprovedSmall moleculeS1P receptorReliable signal
NCT02425644: Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001.
Rebif (interferon Beta 1a)ApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorWeak signalFeatured results are non-efficacy only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)Weak signalFeatured results are non-efficacy only in this race
Rituximab (Rituxan)
Approved(overall)
Monoclonal antibodyCD20, CD20-directed Cytolytic Antibody
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rituximab-Abbs (Truxima)
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Siponimod (Mayzent)ApprovedSmall moleculeS1P receptorWeak signal
NCT01665144: EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results).
Tascenso ODTApprovedSmall moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
Teriflunomide HMR1726 (Aubagio)ApprovedSmall moleculeDihydroorotate dehydrogenase (DHODH)Reliable signal
NCT03122652: Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction)
NCT00751881: Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results).
Tyruko (natalizumab-Sztn)ApprovedMonoclonal antibodyα4 integrinnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)ApprovedMonoclonal antibodyCD20Reliable signal
NCT03277248: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291)
NCT03277261: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.076 relapses per participant-years (95% CI 0.042 to 0.138) | Teriflunomide + IV Placebo 0.188 relapses per participant-years (95% CI 0.124 to 0.283)
ABP 692Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Acellbia
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
BCD-281Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
CT-P53Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 3Monoclonal antibodyCD20Reliable signal
NCT05385744: Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164
FenebrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
FrexalimabPhase 3Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
HLX01 (Hanlikang)
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Nabiximols (Sativex)Phase 3BotanicalCannabinoid CB1/CB2 receptors (agonist)Partial signal
NCT04657666: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) (Baseline (predose Day 1 of Treatment Period 1) up to Day 51 (end of treatment of Treatment Period 2)): Nabiximols -0.23 units on a scale (Standard Error 0.07) vs Placebo -0.26 units on a scale (Standard Error 0.07) missed
NCT01610700: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks): GW-1000-02 -25.32 units on a scale (Standard Deviation 23.42) vs Placebo -19.32 units on a scale (Standard Deviation 27.02) missed
Obinutuzumab Beta (Bejescin)
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
TolebrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)Reliable signal
NCT04411641: HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results).
NCT04458051: 6-month composite confirmed disability progression (cCDP), tolebrutinib vs placebo: HR 1.01 (95% CI 0.81-1.26), p=.94 — no difference from placebo. missed
Vidofludimus CalciumPhase 3—Dihydroorotate dehydrogenase (DHODH)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismPartial signal
NCT04626921: LCLA (Best-Corrected Low-Contrast Letter Acuity) change across both eyes at Week 144 vs original randomization baseline, CNM-Au8 arm: least-squares mean difference +8.70 letters (SE 1.88), 95% CI 5.0 to 12.4, p<0.0001
CorubrutinibPhase 2Small moleculeBruton's tyrosine kinase (BTK)Partial signal
NCT05798520: Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released)
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
IrafamdastatPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
A-005
Phase 1(overall)
Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
IDP-023Phase 1Cell therapyAllogeneic g-NK cell therapynot yet gradedNo reviewed efficacy summary in this indication
SAR448501
Phase 1(overall)
Multispecific antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
RG6035
—(overall)
Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
RG6182
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BaminerceptDiscontinuedProtein / enzyme therapeuticLymphotoxin-beta receptor (LTβR)not yet gradedNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ofatumumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
April 2027 (1)
Phase 4Multiple SclerosisActive not recruiting
Est. primary completion 2027-04-13 · NCT05090371 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Narcolepsy Type 1 (NT1)Recruiting
Est. primary completion 2027-06-30 · NCT07871006 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1Multiple SclerosisNot yet recruiting
Est. primary completion 2027-12-30 · NCT07546110 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
Phase 3Multiple SclerosisActive not recruiting
Est. primary completion 2028-09-30 · NCT03650114 · CT.gov ↗
What to watch

See the full readout calendar ↗